Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudin induces p53 signaling and apoptosis in HTLV-1-infected cells

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Kinpara, Shuichi ^a,b   Kijiyama, Mami ^a   Takamori, Ayako ^a   Hasegawa, Atsuhiko ^a   Sasada, Amane ^a   Masuda, Takao ^a   Tanaka, Yuetsu ^c   Utsunomiya, Atae ^d   Kannagi, Mari ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

^d IMAMURA BUN IN HOSPITAL   (Japan)

Author keywords

Anti viral therapy; ATL; AZT; HTLV 1; IFN ; Innate immunity; p53; PKR

Indexed keywords

ALPHA INTERFERON; PROTEIN KINASE R; PROTEIN P53; TAX PROTEIN; ZIDOVUDINE;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSCRIPTION; HTLV 1 GENE; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANTIVIRAL AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; EIF-2 KINASE; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INTERFERON-ALPHA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEIN P53; ZIDOVUDINE;

HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 84877841844     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-52     Document Type: Article

References (48)

1. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, Shirakawa S, Miyoshi I. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981, 78:6476-6480. 10.1073/pnas.78.10.6476, 349062, 7031654.
2. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977, 50:481-492.
3. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980, 77:7415-7419. 10.1073/pnas.77.12.7415, 350514, 6261256.
4. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de The G. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985, 2:407-410.
5. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986, 1:1031-1032.
6. Kinoshita T, Shimoyama M, Tobinai K, Ito M, Ito S, Ikeda S, Tajima K, Shimotohno K, Sugimura T. Detection of mRNA for the tax1/rex1 gene of human T-cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction. Proc Natl Acad Sci USA 1989, 86:5620-5624. 10.1073/pnas.86.14.5620, 297674, 2787512.
7. Utsunomiya A, Miyazaki Y, Takatsuka Y, Hanada S, Uozumi K, Yashiki S, Tara M, Kawano F, Saburi Y, Kikuchi H. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 27:15-20. 10.1038/sj.bmt.1702731, 11244433.
8. Okamura J, Utsunomiya A, Tanosaki R, Uike N, Sonoda S, Kannagi M, Tomonaga M, Harada M, Kimura N, Masuda M. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 2005, 105:4143-4145. 10.1182/blood-2004-11-4193, 15665110.
9. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2010, 28:1591-1598.
10. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2012, 30:837-842.
11. Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, Buzyn-Veil A, Rio B, Macintyre E, Dreyfus F. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995, 332:1749-1751. 10.1056/NEJM199506293322604, 7760891.
12. Gill PS, Harrington W, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995, 332:1744-1748. 10.1056/NEJM199506293322603, 7760890.
13. Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G, Hermine O. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2010, 28:4177-4183.
14. Harashima N, Kurihara K, Utsunomiya A, Tanosaki R, Hanabuchi S, Masuda M, Ohashi T, Fukui F, Hasegawa A, Masuda T. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res 2004, 64:391-399. 10.1158/0008-5472.CAN-03-1452, 14729650.
15. Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004, 64:2127-2133. 10.1158/0008-5472.CAN-03-2068, 15026353.
16. Bazarbachi A, Nasr R, El-Sabban ME, Mahe A, Mahieux R, Gessain A, Darwiche N, Dbaibo G, Kersual J, Zermati Y. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2000, 14:716-721.
17. Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M, Rafatpanah H. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009, 113:6528-6532. 10.1182/blood-2009-03-211821, 19411628.
18. El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F, Ameisen JC, Bex F, de The H, Bazarbachi A. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood 2000, 96:2849-2855.
19. El Hajj H, El-Sabban M, Hasegawa H, Zaatari G, Ablain J, Saab ST, Janin A, Mahfouz R, Nasr R, Kfoury Y. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J Exp Med 2010, 207:2785-2792. 10.1084/jem.20101095, 3005222, 21135137.
20. Feng X, Heyden NV, Ratner L. Alpha interferon inhibits human T-cell leukemia virus type 1 assembly by preventing Gag interaction with rafts. J Virol 2003, 77:13389-13395. 10.1128/JVI.77.24.13389-13395.2003, 296084, 14645593.
21. Feng X, Ratner L. Human T-cell leukemia virus type 1 blunts signaling by interferon alpha. Virology 2008, 374:210-216. 10.1016/j.virol.2007.12.036, 2373983, 18234266.
22. Zhang J, Yamada O, Kawagishi K, Araki H, Yamaoka S, Hattori T, Shimotohno K. Human T-cell leukemia virus type 1 Tax modulates interferon-alpha signal transduction through competitive usage of the coactivator CBP/p300. Virology 2008, 379:306-313. 10.1016/j.virol.2008.06.035, 18678383.
23. Oliere S, Hernandez E, Lezin A, Arguello M, Douville R, Nguyen TL, Olindo S, Panelatti G, Kazanji M, Wilkinson P. HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1). PLoS Pathog 2010, 6:e1001177. 10.1371/journal.ppat.1001177, 2973829, 21079688.
24. Charoenthongtrakul S, Zhou Q, Shembade N, Harhaj NS, Harhaj EW. Human T cell leukemia virus type 1 Tax inhibits innate antiviral signaling via NF-kappaB-dependent induction of SOCS1. J Virol 2011, 85:6955-6962. 10.1128/JVI.00007-11, 3126571, 21593151.
25. Suzuki S, Zhou Y, Refaat A, Takasaki I, Koizumi K, Yamaoka S, Tabuchi Y, Saiki I, Sakurai H. Human T cell lymphotropic virus 1 manipulates interferon regulatory signals by controlling the TAK1-IRF3 and IRF4 pathways. J Biol Chem 2010, 285:4441-4446. 10.1074/jbc.M109.031476, 2836049, 19955181.
26. Kinpara S, Hasegawa A, Utsunomiya A, Nishitsuji H, Furukawa H, Masuda T, Kannagi M. Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon. J Virol 2009, 83:5101-5108. 10.1128/JVI.02564-08, 2682107, 19264779.
27. Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol 2001, 19:475-496. 10.1146/annurev.immunol.19.1.475, 11244044.
28. Jeang KT. Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-kappa B. Cytokine Growth Factor Rev 2001, 12:207-217. 10.1016/S1359-6101(00)00028-9, 11325603.
29. Saitoh Y, Yamamoto N, Dewan MZ, Sugimoto H, Martinez Bruyn VJ, Iwasaki Y, Matsubara K, Qi X, Saitoh T, Imoto I. Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells. Blood 2008, 111:5118-5129. 10.1182/blood-2007-09-110635, 18305221.
30. Takemoto S, Trovato R, Cereseto A, Nicot C, Kislyakova T, Casareto L, Waldmann T, Torelli G, Franchini G. p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14(ARF)-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. Blood 2000, 95:3939-3944.
31. Dey M, Cao C, Dar AC, Tamura T, Ozato K, Sicheri F, Dever TE. Mechanistic link between PKR dimerization, autophosphorylation, and eIF2alpha substrate recognition. Cell 2005, 122:901-913. 10.1016/j.cell.2005.06.041, 16179259.
32. Dar AC, Dever TE, Sicheri F. Higher-order substrate recognition of eIF2alpha by the RNA-dependent protein kinase PKR. Cell 2005, 122:887-900. 10.1016/j.cell.2005.06.044, 16179258.
33. Zhang F, Romano PR, Nagamura-Inoue T, Tian B, Dever TE, Mathews MB, Ozato K, Hinnebusch AG. Binding of double-stranded RNA to protein kinase PKR is required for dimerization and promotes critical autophosphorylation events in the activation loop. J Biol Chem 2001, 276:24946-24958. 10.1074/jbc.M102108200, 11337501.
34. Fujisawa J, Seiki M, Kiyokawa T, Yoshida M. Functional activation of the long terminal repeat of human T-cell leukemia virus type I by a trans-acting factor. Proc Natl Acad Sci USA 1985, 82:2277-2281. 10.1073/pnas.82.8.2277, 397540, 2986109.
35. Sodroski JG, Goh WC, Rosen CA, Salahuddin SZ, Aldovini A, Franchini G, Wong-Staal F, Gallo RC, Sugamura K, Hinuma Y. trans-Activation of the human T-cell leukemia virus long terminal repeat correlates with expression of the x-lor protein. J Virol 1985, 55:831-835. 255069, 2991599.
36. Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW, Yamamoto N. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood 1999, 93:2360-2368.
37. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003, 424:516-523. 10.1038/nature01850, 12872134.
38. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008, 9:402-412. 10.1038/nrm2395, 18431400.
39. Balint EE, Vousden KH. Activation and activities of the p53 tumour suppressor protein. Br J Cancer 2001, 85:1813-1823. 10.1054/bjoc.2001.2128, 2364002, 11747320.
40. Newcomb EW. P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk Lymphoma 1995, 17:211-221. 10.3109/10428199509056825, 8580789.
41. Pise-Masison CA, Mahieux R, Radonovich M, Jiang H, Brady JN. Human T-lymphotropic virus type I Tax protein utilizes distinct pathways for p53 inhibition that are cell type-dependent. J Biol Chem 2001, 276:200-205.
42. Ariumi Y, Kaida A, Lin JY, Hirota M, Masui O, Yamaoka S, Taya Y, Shimotohno K. HTLV-1 tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration. Oncogene 2000, 19:1491-1499. 10.1038/sj.onc.1203450, 10734308.
43. Datta A, Bellon M, Sinha-Datta U, Bazarbachi A, Lepelletier Y, Canioni D, Waldmann TA, Hermine O, Nicot C. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 2006, 108:1021-1029. 10.1182/blood-2006-01-0067, 1895862, 16569765.
44. Schneider U, Schwenk HU, Bornkamm G. Characterization of EBV-genome negative " null" and " T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. International journal of cancer Journal international du cancer 1977, 19:621-626. 10.1002/ijc.2910190505, 68013.
45. Minowada J, Onuma T, Moore GE. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 1972, 49:891-895.
46. Lee B, Tanaka Y, Tozawa H. Monoclonal antibody defining tax protein of human T-cell leukemia virus type-I. Tohoku J Exp Med 1989, 157:1-11. 10.1620/tjem.157.1, 2711372.
47. Tanaka Y, Lee B, Inoi T, Tozawa H, Yamamoto N, Hinuma Y. Antigens related to three core proteins of HTLV-I (p24, p19 and p15) and their intracellular localizations, as defined by monoclonal antibodies. International journal of cancer Journal international du cancer 1986, 37:35-42. 10.1002/ijc.2910370107, 3000953.
48. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985, 82:7096-7100. 10.1073/pnas.82.20.7096, 391317, 2413459.